Functional mechanism of the enhancement of 5‑fluorouracil sensitivity by TUSC4 in colon cancer cells

Liu,Ming‑Na; Liu,Ai‑Yun; Pei,Feng‑Hua; Ma,Xiao; Fan,Yu‑Jing; Du,Ya‑Ju; Liu,Bing‑Rong

doi:10.3892/ol.2015.3801

Functional mechanism of the enhancement of 5‑fluorouracil sensitivity by TUSC4 in colon cancer cells

Authors:
- Ming‑Na Liu
- Ai‑Yun Liu
- Feng‑Hua Pei
- Xiao Ma
- Yu‑Jing Fan
- Ya‑Ju Du
- Bing‑Rong Liu
View Affiliations

Affiliations: Department of Gastroenterology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150080, P.R. China
Published online on: October 13, 2015 https://doi.org/10.3892/ol.2015.3801
Pages: 3682-3688

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

5‑Fluorouracil (5‑FU) is the chemotherapeutic drug of choice for the treatment of metastatic colorectal cancer (CRC). Tumor suppressor candidate 4 (TUSC4), also referred to as nitrogen permease regulator‑like 2 (NPRL2), is located at chromosome 3p21.3 and expressed in numerous normal tissues, including the heart, liver, skeletal muscle, kidney, and pancreas. The aim of the present study was to investigate the functional mechanism by which TUSC4 affects sensitivity to 5‑FU and to determine its clinical significance in CRC. The results of the present study demonstrated that TUSC4 overexpression increases the sensitivity of HCT116 cells to 5‑FU. The IC50 of 5‑FU was reduced in cells transduced with TUSC4 compared with negative control (NC) cells, and the effect of TUSC4 on 5‑FU sensitivity was time dependent. Following TUSC4 transduction in HCT116 cells, a proportion of the cells were arrested in the G1 phase of the cell cycle, and a reduction in the S phase population was observed. Flow cytometry analysis revealed that TUSC4 transduction and 5‑FU treatment increased apoptosis compared with NC cells. The mechanism through which TUSC4 overexpression enhances 5‑FU sensitivity involves the downregulation of the function of the PI3K/Akt/mTOR network. Furthermore, 5‑FU upregulated caspase‑3 and caspase‑9, promoting apoptosis in TUSC4‑overexpressing cells compared with cells that were transduced with TUSC4 or treated with 5‑FU and NC cells. The findings of the present study indicate that TUSC4 has potential as a biomarker for the prediction of the response to 5‑FU and prognosis in patients with colorectal cancer and other types of human cancer. TUSC4 may also act as a molecular therapeutic agent for enhancing the patient's response to 5‑FU treatment.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Patel BB and Majumdar AP: Synergistic role of curcumin with current therapeutics in colorectal cancer: Minireview. Nutr Cancer. 61:842–6. 2009. View Article : Google Scholar : PubMed/NCBI
3	Borralho PM, da Silva Moreira IB, Aranha MM, Albuquerque C and Nobre Leitao C: Inhibition of Fas expression by RNAi modulates 5-fluorouracilinduced apoptosis in HCT116 cells expressing wild-type p53. Biochim Biophys Acta. 1772:40–47. 2007. View Article : Google Scholar : PubMed/NCBI
4	Peters GJ, van Triest B, Backus HH, Kuiper CM, van der Wilt CL and Pinedo HM: Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer. 36:916–924. 2000. View Article : Google Scholar : PubMed/NCBI
5	Lerman MI and Minna JD: The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes. The International lung cancer chromosome 3p21.3 tumor suppressor gene consortium. Cancer Res. 60:6116–6133. 2000.PubMed/NCBI
6	Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon JW III, Garner HR, McKay B, Latif F, et al: High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 60:1949–1960. 2000.PubMed/NCBI
7	Zabarovsky ER, Lerman MI and Minna JD: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene. 21:6915–6935. 2002. View Article : Google Scholar : PubMed/NCBI
8	Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C, Xu K, Yen N, Atkinson EN, Fang B, et al: Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res. 62:2715–2720. 2002.PubMed/NCBI
9	Schenk PW, Brok M, Boersma AW, Brandsma JA, Den Dulk H, Burger H, Stoter G, Brouwer J and Nooter K: Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: A novel component involved in cisplatin- and doxorubicin-provoked cell kill. Mol Pharmacol. 64:259–268. 2003. View Article : Google Scholar : PubMed/NCBI
10	Ueda K, Kawashima H, Ohtani S, Deng WG, Ravoori M, Bankson J, Gao B, Girard L, Minna JD and Roth JA: The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res. 66:9682–9690. 2006. View Article : Google Scholar : PubMed/NCBI
11	Li J, Wang F, Haraldson K, Protopopov A, Duh FM, Geil L, Kuzmin I, Minna JD, Stanbridge E, Braga E, et al: Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C. Cancer Res. 64:6438–6443. 2004. View Article : Google Scholar : PubMed/NCBI
12	Jayachandran G, Ueda K, Wang B, Roth JA and Ji L: NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway. PLoS One. 8:e119942010. View Article : Google Scholar
13	Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International multicentre pooled analysis of colon cancer trials (IMPACT) investigators. Lancet. 345:939–944. 1995. View Article : Google Scholar : PubMed/NCBI
14	Johnston PG and Kaye S: Capecitabine: A novel agent for the treatment of solid tumors. Anticancer Drugs. 12:639–646. 2001. View Article : Google Scholar : PubMed/NCBI
15	Zhou BB and Elledge SJ: The DNA damage response: Putting checkpoints in perspective. Nature. 408:433–439. 2000. View Article : Google Scholar : PubMed/NCBI
16	Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, Weiss HL and Evers BM: Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg. 210:767–776. 2010. View Article : Google Scholar : PubMed/NCBI
17	Maira SM, Voliva C and Garcia-Echeverria C: Class IA phosphatidylinositol 3-kinase: From their biologic implication in human cancers to drug discovery. Exp Opin Ther Targets. 12:223–238. 2008. View Article : Google Scholar
18	Ekstrand AI, Jönsson M, Lindblom A, Borg A and Nilbert M: Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam Cancer. 9:125–129. 2010. View Article : Google Scholar : PubMed/NCBI
19	Samuels Y and Ericson K: Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 18:77–82. 2006. View Article : Google Scholar : PubMed/NCBI
20	Vignot S, Faivre S, Aguirre D and Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 16:525–537. 2005. View Article : Google Scholar : PubMed/NCBI
21	Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar : PubMed/NCBI
22	Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Cajal Ramony S, Jones S, Vidal L, et al: Doseand-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 26:1603–1610. 2008. View Article : Google Scholar : PubMed/NCBI
23	Proud CG: mTORC1 signalling and mRNA translation. Biochem Soc Trans. 37:227–231. 2009. View Article : Google Scholar : PubMed/NCBI
24	Xu G, Zhang W, Bertram P, Zheng XF and McLeod H: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol. 24:893–900. 2004.PubMed/NCBI
25	Armegnol G, Rojo F, CastellviĹ J, Iglesias C, Cuatrecasas M, Pons B, Baselga J, Ramón Y and Cajal S: 4E-binding protein 1: A key molecular ‘funnel factor’ in human cancer with clinical implications. Cancer Res. 67:7551–7555. 2007. View Article : Google Scholar : PubMed/NCBI